Thursday, November 29, 2012
Publication and contact
Programmed cell death 1
T cells for HPV-positive head and neck cancer prognosis
In vitro and mouse studies suggest levels of PD-1-expressing
T cells could be useful as a prognostic marker and help guide treatment for
HPV-positive head and neck cancer. In 32 patients with HPV-positive head and
neck cancers, survival rates and levels of PD-1-expressing T cells were
higher than those for 32 patients with HPV-negative cancers. In a mouse HPV
tumor model, an antibody targeting the PD-1 ligand programmed
cell death 1 ligand 1 (CD274 molecule;
increased the antitumor effect of an HPV cancer vaccine targeting E7
transforming protein (human
papillomavirus-16; HpV16gp1) compared with control
antibodies. Next steps include validating the biomarker findings and testing
anti-PD-1 antibodies in clinical trials.
At least eight companies have antibodies targeting PD-1 or PD-L1 in Phase II
testing or earlier to treat various cancers.
SciBX 5(46); doi:10.1038/scibx.2012.1221
Published online Nov. 29, 2012
licensing not applicable
Badoual, C. et al.
Cancer Res.; published online Nov. 7, 2012;
Contact: Eric Tartour, Georges Pompidou European Hospital,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]